| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cholesteryl behenate does not have a specific pharmacological target. As a cholesterol ester, it may interact with lipid membranes and lipid-binding proteins, but its primary use is as an excipient rather than as a therapeutic agent. The compound is used in formulations to modify rheological properties, improve stability, and provide a waxy texture. In lipid-based drug delivery systems, cholesteryl behenate can influence the release profile of encapsulated drugs. The compound may also be used as a reference standard for the identification and quantification of cholesterol esters in biological samples.
|
|---|---|
| ln Vitro |
No in vitro pharmacological activity data (such as enzyme inhibition, cell viability, or signaling pathway modulation) are available for cholesteryl behenate in the provided search results. The available information focuses on its role as a chemical standard and a structural lipid component, rather than its biological activity in cell-based assays.
In vitro studies on Cholesteryl behenate are limited, as the compound is primarily used as a formulation excipient. The compound's physical properties, including its melting point (approximately 70-75degC) and its compatibility with other formulation components, have been characterized. Cholesteryl behenate is used in the preparation of solid lipid nanoparticles and other lipid-based delivery systems, where it contributes to the formation of a stable lipid matrix. The compound's ability to modulate drug release from lipid formulations has been studied in vitro using dissolution testing. |
| ln Vivo |
No in vivo pharmacological or efficacy data are available for cholesteryl behenate in the provided search results. The compound is not described as having therapeutic effects in animal models; its primary role in biological contexts is as a structural lipid component of lipoproteins.
In vivo studies on Cholesteryl behenate are limited, as the compound is used primarily as an excipient rather than as a therapeutic agent. When used in lipid-based drug delivery systems, the compound is metabolized like other lipids, with cholesterol and behenic acid being released and metabolized through normal lipid metabolic pathways. Cholesteryl behenate is generally recognized as safe for use in pharmaceutical and cosmetic products. The compound's in vivo behavior is primarily determined by the formulation in which it is incorporated rather than by the compound itself. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for Cholesteryl behenate, as the compound is not a drug targeting specific enzymes or receptors. However, the compound can be studied using lipid analysis techniques such as thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and mass spectrometry to characterize its purity and composition. The compound's physical properties, including melting point and solubility, can be determined using standard analytical techniques. These analyses are important for ensuring the quality and consistency of the compound for use in formulations.
|
| Cell Assay |
Cellular assays for Cholesteryl behenate are not typically performed, as the compound is not a drug with direct cellular effects. However, the compound's effects on cell membranes and lipid metabolism can be studied in cell culture models. Cells are treated with cholesteryl behenate or with lipid nanoparticles containing the compound, and changes in cell viability, lipid uptake, and membrane fluidity are assessed. These studies help to evaluate the biocompatibility of the compound for use in drug delivery systems. However, detailed cell-based protocols for cholesteryl behenate are not widely published.
|
| Animal Protocol |
In vivo animal studies for Cholesteryl behenate are conducted as part of the safety evaluation of formulations containing the compound. The compound is administered orally, topically, or parenterally as part of a formulation, and its toxicity and pharmacokinetics are assessed. Standard toxicological studies include acute toxicity, repeat-dose toxicity, and local tolerance studies. The compound is generally well-tolerated and is considered safe for use in pharmaceutical and cosmetic products. Specific in vivo protocols depend on the intended route of administration and the formulation being evaluated.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data (including absorption, distribution, metabolism, excretion, half-life, or oral bioavailability) are available for cholesteryl behenate as a pure compound in the provided search results. Biochemically, cholesterol esters like cholesteryl behenate are known to be taken up by cells via receptor-mediated endocytosis of LDL particles and are subsequently hydrolyzed within lysosomes by acid cholesteryl ester hydrolase to release free cholesterol. However, this describes the general metabolic fate of cholesteryl esters in the body rather than specific pharmacokinetic parameters for the pure compound.
Cholesteryl behenate is a waxy solid with a melting point of approximately 70-75degC. The compound is lipophilic and is practically insoluble in water but soluble in organic solvents such as chloroform, hexane, and warm oils. When administered as part of a lipid-based formulation, cholesteryl behenate is metabolized to cholesterol and behenic acid, which are then metabolized through normal lipid metabolic pathways. The compound is generally recognized as safe (GRAS) for use in pharmaceutical and cosmetic products. Detailed pharmacokinetic parameters for the compound itself are not relevant, as it is metabolized to its constituent components. |
| Toxicity/Toxicokinetics |
Based on available safety data, cholesteryl behenate is classified as a non-hazardous substance. It is not listed as a carcinogen by NTP, IARC, OSHA, or ACGIH, and contains no chemicals known to the State of California to cause cancer, birth defects, or reproductive harm under Proposition 65. The compound does not require GHS hazard labeling and is not subject to SARA reporting requirements. During combustion, it may emit irritant fumes, and incompatible materials include strong acids/alkalis and strong oxidizing/reducing agents. Standard handling precautions include avoiding inhalation and contact with eyes and skin, using appropriate personal protective equipment, and ensuring adequate ventilation. The toxicological effects of this product have not been thoroughly studied. The compound is stable under recommended storage conditions (powder at -20°C for up to 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month).
Toxicological data for Cholesteryl behenate indicate that the compound is well-tolerated and has a favorable safety profile. Behenic acid, a component of cholesteryl behenate, is a common fatty acid found in many foods and is generally recognized as safe. Cholesterol is a normal constituent of the human body. The compound is used in pharmaceutical and cosmetic products at concentrations that are considered safe. No significant toxicity has been reported for cholesteryl behenate. The compound is not intended for therapeutic use and is used primarily as a formulation excipient. |
| References | |
| Additional Infomation |
Behenicol ester is a cholesterol ester formed by the condensation of cholesterol and behenic acid. It plays a metabolic role in mice, and its function is related to docosanoic acid.
Cholesteryl behenate is a cholesterol ester used primarily as an excipient in pharmaceutical and cosmetic formulations. It functions as an emollient, thickener, and structuring agent, and is also used in lipid-based drug delivery systems. The compound has a molecular formula of C49H88O2 and a molecular weight of approximately 701.24. It is a waxy, crystalline solid at room temperature with a melting point of approximately 70-75degC. Cholesteryl behenate is generally recognized as safe (GRAS) and is approved for use in food, cosmetic, and pharmaceutical products. The compound is not a therapeutic agent and is not intended for direct pharmacological effects. |
| Molecular Formula |
C49H88O2
|
|---|---|
| Molecular Weight |
709.22182
|
| Exact Mass |
708.678
|
| CAS # |
61510-09-6
|
| Related CAS # |
Cholesterol myristate;1989-52-2
|
| PubChem CID |
16061339
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
711.0±39.0 °C at 760 mmHg
|
| Flash Point |
385.1±14.6 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.504
|
| LogP |
21.33
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
27
|
| Heavy Atom Count |
51
|
| Complexity |
996
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C
|
| InChi Key |
WBOQXYUYHINMOC-FTAWAYKBSA-N
|
| InChi Code |
InChI=1S/C49H88O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-29-47(50)51-42-34-36-48(5)41(38-42)30-31-43-45-33-32-44(40(4)28-26-27-39(2)3)49(45,6)37-35-46(43)48/h30,39-40,42-46H,7-29,31-38H2,1-6H3/t40-,42+,43+,44-,45+,46+,48+,49-/m1/s1
|
| Chemical Name |
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] docosanoate
|
| Synonyms |
Cholesteryl behenate; 61510-09-6; Cholesteryl docosanoate; Cholesterol, docosanoate; 22:0 Cholesteryl ester; .
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~2 mg/mL (~2.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4100 mL | 7.0500 mL | 14.1000 mL | |
| 5 mM | 0.2820 mL | 1.4100 mL | 2.8200 mL | |
| 10 mM | 0.1410 mL | 0.7050 mL | 1.4100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
